Journal
PEDIATRIC INFECTIOUS DISEASE JOURNAL
Volume 41, Issue 5, Pages 417-419Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/INF.0000000000003467
Keywords
Hepatitis C; HIV; treatment; adolescents; pediatric; direct-acting antivirals
Categories
Funding
- Penta Foundation
- ViiV Healthcare
- BMS (Penta Foundation)
- Abbvie
- Bristol Myers Squibb
- Gilead
- Janssen Pharmaceuticals
- ViiV Healthcare (Penta Foundation)
Ask authors/readers for more resources
This study evaluated the real-world safety and effectiveness of direct-acting antivirals (DAAs) in HIV/HCV coinfected adolescents from the Ukraine Paediatric HIV Cohort Study. The results showed that DAA treatment was well tolerated and effective in these patients.
Direct-acting antivirals (DAAs) have been approved for treating chronic hepatitis C virus (HCV) in children and adolescents. Although DAAs have been used in real-world settings for the treatment of HCV monoinfected adolescents, few reports of real-world use of DAAs in children and adolescents who are coinfected with human immunodeficiency virus (HIV) are available. We evaluated the real-world safety and effectiveness of DAAs in HIV/HCV coinfected adolescents from the Ukraine Paediatric HIV Cohort Study including all those for whom treatment outcomes were available by April 2021. Overall, 6 coinfected adolescents had received DAA treatment; 4 with sofosbuvir/ledipasvir (SOF/LDV), 1 with SOF/LDV+ribavirin, and 1 with SOF/daclatasvir. No patient discontinued treatment due to adverse events and no serious adverse events were reported. All 6 patients achieved sustained virologic response by 12 weeks after the end of therapy. DAA treatment was well tolerated and effective in adolescents with HIV/HCV coinfection in a real-world setting.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available